跳转至内容
Merck
CN

O1014

Octreotide

≥98% (HPLC), Somatostatin receptor agonist,

别名:

SMS 201-995

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C49H66N10O10S2
化学文摘社编号:
83150-76-9
分子量:
1019.24
UNSPSC Code:
12352200
PubChem Substance ID:
329818892
NACRES:
NA.32
MDL number:
MFCD00871400

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Octreotide, ≥98% (HPLC)

SMILES string

C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

InChI key

DEQANNDTNATYII-OULOTJBUSA-N

InChI

1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

assay

≥98% (HPLC)

solubility

H2O: soluble

storage temp.

−20°C

Quality Level

200

Gene Information

human ... SSTR1(6751), SSTR2(6752), SSTR3(6753), SSTR4(6754), SSTR5(6755)

正在寻找类似产品? 访问 产品对比指南

相关类别

General description

Octreotide is a somatostatin analogue with D-Phe-Cys-Phe-D-Trp-Lys-ThrCys-Thr-OH amino acid sequence.

Biochem/physiol Actions

Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment.
Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.

Other Notes

Lyophilized from 0.1% TFA in H2O

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000461550
0000461550
0000388957
0000388957
0000235385

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Octreotide as primary therapy for acromegaly.
Newman CB
The Journal of Clinical Endocrinology and Metabolism, 83(9), 3034-3040 (1998)
Jan Calissendorff et al.
Endocrine, 47(1), 169-176 (2013-11-26)
Metastases from ileal neuroendocrine tumors (NETs) to the myocardium are rare and generally seen in patients with widespread metastatic NET disease. The objectives of this investigation were to describe the frequency of intracardiac metastases in ileal NET patients examined by
Odaly Toffoletto et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 30-31, 31-36 (2016-09-23)
To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of growth hormone was conducted. The test formulation (biosimilar recombinant human growth hormone; r-hGH; Somatotropin) and reference
Animitra Das et al.
The Cochrane database of systematic reviews, (9)(9), CD006388-CD006388 (2010-09-09)
Routine care for chylothorax in neonate includes either conservative or surgical approaches. Octreotide, a somatostatin analogue, has been used for the management of patients with refractory chylothorax not responding to conservative management. To assess the efficacy and safety of octreotide
Anders Sundin
Best practice & research. Clinical gastroenterology, 26(6), 803-818 (2013-04-16)
Neuroendocrine tumours (NETs) comprise a heterogeneous group of neoplasms with very varying clinical expression. A functioning NET, for instance in the pancreas, may be very small and yet give rise to severe endocrine symptoms whereas a patient with a small
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持